Conolidine’s analgesic effects stem from its interaction with non-opioid pain pathways. Unlike opioids, which bind to µ-opioid receptors inside the central anxious process, conolidine modulates alternate molecular targets. A Science Developments review identified that conolidine interacts While using the atypical chemokine receptor ACKR3/CXCR7, which regulates opioid peptide availabil... https://richardg531cfg2.smblogsites.com/profile